StoxAster DM Quality Care vs Piramal Pharma: share price & financials comparison
NSE: ASTERDM vs PPLPHARMA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Aster DM Quality Care vs Piramal Pharma at a glance
Aster DM Quality Care (ASTERDM) has a market capitalisation of ₹62,979 Cr, against ₹32,484 Cr for Piramal Pharma (PPLPHARMA). Over the past year Piramal Pharma has returned +22.0%, compared with +4.9% for Aster DM Quality Care. Aster DM Quality Care earns a higher return on equity (6.0% vs -2.6%). Aster DM Quality Care comes out ahead on size, profitability and financial health. Piramal Pharma comes out ahead on momentum and technicals. Across the scored metrics below, Aster DM Quality Care leads on 8 and Piramal Pharma on 6. On StoxGud's 10-point checklist, Aster DM Quality Care scores 5/10 and Piramal Pharma scores 6/10.
| Metric | Aster DM Quality Care | Piramal Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹62,979 Cr | ₹32,484 Cr |
| Revenue (latest FY) | ₹4,643 Cr | ₹8,869 Cr |
| Net profit (latest FY) | ₹388 Cr | ₹-326 Cr |
| Valuation | ||
| P/E | 133.8 | — |
| P/B | 8.08 | 3.99 |
| Dividend yield | 0.09% | 0.06% |
| Profitability | ||
| Return on equity | 6.0% | -2.6% |
| Net profit margin | 7.2% | -2.1% |
| Operating margin | 21.1% | 12.3% |
| Growth | ||
| Revenue growth (YoY) | +136.3% | +28.1% |
| Net profit growth (YoY) | +138.2% | — |
| Revenue CAGR (multi-year) | -11.6% | +7.8% |
| Financial health | ||
| Debt to equity | 0.51 | 0.70 |
| Momentum | ||
| 1-month return | +4.7% | +24.8% |
| 1-year return | +4.9% | +22.0% |
| 3-year CAGR | +28.3% | +26.7% |
| 5-year CAGR | +28.4% | — |
| Distance from 52W high | -16.9% | -0.7% |
| Technicals | ||
| RSI (14) | 76 | 86 |
| Price vs 200-day avg | +0.5% | +35.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Aster DM Quality Care | Piramal Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 5/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Aster DM Quality Care or Piramal Pharma?
Aster DM Quality Care has a market cap of ₹62,979 Cr and Piramal Pharma has a market cap of ₹32,484 Cr as of 13 Nov 2026.
Which gave better returns in the last year, Aster DM Quality Care or Piramal Pharma?
Piramal Pharma did better: Aster DM Quality Care returned +4.9% and Piramal Pharma returned +22.0% over one year.
What is the difference between Aster DM Quality Care and Piramal Pharma?
Both are NSE-listed companies in Healthcare. Aster DM Quality Care is about 1.9 times the size of Piramal Pharma by market cap. In the latest financial year Aster DM Quality Care reported revenue of ₹4,643 Cr and Piramal Pharma ₹8,869 Cr. Operating margin is 21.1% for Aster DM Quality Care and 12.3% for Piramal Pharma. Debt to equity is 0.51 for Aster DM Quality Care and 0.70 for Piramal Pharma.
Which is better, Aster DM Quality Care or Piramal Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Aster DM Quality Care leads on 8 and Piramal Pharma on 6. Aster DM Quality Care is ahead on size, profitability and financial health. Piramal Pharma is ahead on momentum and technicals. On StoxGud's rules-based checklist Aster DM Quality Care scores 5/10 and Piramal Pharma scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.